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amyloid complexes. NMr and molecular docking demon-
strated transient interactions between native S100A9 and 
Aβ. Thus, abundantly present in AD brain pro-inflammatory 
S100A9, possessing also intrinsic amyloidogenic properties 
and ability to modulate Aβ aggregation, can serve as a link 
between the AD amyloid and neuroinflammatory cascades 
and as a prospective therapeutic target.
Keywords Aβ · Alzheimer’s disease · Amyloid · 
Cytotoxicity · Neuroinflammation · S100A9 · Traumatic 
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Introduction
The amyloid cascade with the leading role of amyloid-β 
(Aβ) peptides remains a central concept of Alzheimer’s dis-
ease (AD) pathology. AD brains contain soluble (neurotoxic 
oligomers) and insoluble (plaques) assemblies of Aβ, both 
of which are the focus of intensive research with the aim of 
using them as targets for potential therapeutic intervention 
and raising the possibility that their elimination will lead to 
an AD cure [36, 44]. Yet the causes triggering Aβ aberrant 
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accumulation in relatively late age still remain elusive and a 
second causal event may be required to turn on this patho-
logical cascade. Chronic or acute inflammation, associated 
for example with traumatic brain injury (TBI), may fulfill this 
function and currently they are the subject of increasing atten-
tion [3, 14]. The role of inflammation in AD is supported by 
a sharp induction of inflammatory mediators in AD-affected 
brain [25] as well as by epidemiological and experimental 
studies demonstrating that non-steroidal anti-inflammatory 
drugs markedly reduce the age-related prevalence of AD [7, 
17]. Moreover, these drugs can slow down amyloid deposi-
tion by mechanisms that remain still unknown [7]. In this 
research, we show that the pro-inflammatory protein S100A9 
can serve as a critical link between the amyloid cascade and 
inflammatory events in AD pathology.
S100A9 acts as a pro-inflammatory mediator and its 
elevated level was found in many inflammatory condi-
tions, including inflammation-associated AD [37]. A sig-
nificantly increased microglia expression of S100A9 was 
observed in the temporal cortex of both familial and spo-
radic AD cases compared to old and young controls [37]. 
In this study S100A9-positive glia was associated with Aβ 
diffuse deposits and plaques. The Western blot analysis 
of the brain extracts also revealed a significantly elevated 
level of S100A9 monomers and high molecular weight 
complexes in AD [37], resembling similar dynamics of Aβ 
expression in AD [36]. Therefore, the authors raised the 
question as whether S100A9 is involved in plaque pathol-
ogy [37]. Kummer and coauthors [23] observed a signifi-
cantly increased level of S100A9 (which is denoted also 
as myeloid-related protein Mrp14 [40]) in the brain lysates 
and cerebrospinal fluid of AD patients compared to age-
matched controls and detected S100A9-positive micro-
glial cells in the vicinity of amyloid plaques—thus all data 
implicated S100A9 as a neuroinflammatory marker of AD. 
A widespread expression of S100A9 was reported in the 
brain in malaria [34], cerebral ischemia [30] and TBI [10], 
where it may initiate sustainable inflammatory responses 
and perform cytokine-like functions controlling inflamma-
tory responses of other cells. In an AD mice model S100A9 
production was induced by both Aβ peptide and the C-ter-
minal fragment of the amyloid precursor protein, while 
S100A9 knockdown attenuated memory impairment and 
reduced amyloid plaque burden [16]. In AD APP/PS1 mice 
S100A9 was found to be up-regulated in microglial cells, 
while the loss of S100A9 by targeted gene disruption led 
to reduction of the pro-inflammatory cytokine production 
with dual consequences [23]. Firstly, reduced inflammation 
decreased the transcription of BACe1 and BACe2, thus 
limiting the Aβ production and its consequent deposition. 
Secondly, prevention of excessive microglial activation 
favored amyloid degradation by microglial phagocytosis, 
thus acting to protect against AD pathology.
In our previous studies, we have found that the rise of 
S100A9 level during inflammation may lead to its amyloid 
formation and deposition in the aging prostate [45] and in 
the yeast cell model [11]. Both granulocyte extracted and 
recombinant S100A8/S100A9 complexes formed amyloid 
oligomers and fibrils also in vitro and the amyloid propen-
sity analysis of S100A8 and S100A9 amino acid sequences 
revealed that they are intrinsically amyloidogenic [45]. 
generally amyloid propensity of S100 protein family was 
related to their intrinsically disordered sequences, which 
can be exposed upon loss of structural protection in the 
native tertiary or quaternary folds and become accessible to 
amyloid-competent conformations [6]. It has been shown 
that in vitro the mixture of monomeric and dimeric S100A9 
may also induce Aβ fibrillation, suggesting some interac-
tions between S100A9 monomer/dimer and Aβ aggregates, 
though these interactions remained elusive [47]. Such 
interactions ultimately reduced the cytotoxicity attrib-
uted in this study to non-aggregated S100A9 [47]. The 
contacts between S100A9 and short Aβ(12–24) peptide, 
corresponding to the hydrophobic core of full-length Aβ 
peptides, were analyzed with an atomic resolution by rep-
lica exchange molecular dynamics simulation [48]. It was 
demonstrated that the hydrogen bonding between S100A9 
and the ends of this core Aβ peptide induced Aβ(12–24) 
straightening and consequently promoted its oligomeriza-
tion. Interestingly, in vitro amyloid fibrillation was found 
also to be a property of another protein from S100 family—
S100A6, as well as its seeding capacity for superoxide dis-
mutase-1 aggregation, which may be related to the amylo-
tropic lateral sclerosis pathology [4].
It is important to note that recently the abundance of 
S100A9 mrNA was identified as a strong feature of aging 
in various mammalian tissues, including the central nervous 
system, and a novel mechanism of age-associated inflam-
mation sustained by S100A9 was suggested [38]. However, 
the specific role of S100A9 in AD as well as in aging is still 
far from clear. Here, by using combined analysis of ex vivo 
AD-affected brain tissues and modeling S100A9 aggrega-
tion and co-aggregation with Aβ in vitro, we demonstrate 
the direct involvement of S100A9 in AD basic mechanisms 
from the perspective of its intrinsic amyloidogenicity, abil-
ity to form plaques and neurotoxicity, thus bridging the AD 
neuroinflammatory and amyloid cascades.
Materials and methods
Materials
Aβ(1–40) and Aβ(1–42) (Alexotech, Sweden) were 
used in all experiments. Both peptides were dissolved in 
10 mM NaOH to avoid aggregation and then diluted into 
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phosphate buffered saline (PBS—140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4) 10 mM PBS, 
pH 7.4 to the required final concentration, determined by 
Bradford assay and by absorbance at 220 nm [2]. This 
preparation method, described in more detail in [42], yields 
highly uniform and reproducible samples well suited for 
NMr and other spectroscopic and aggregation studies [12]. 
S100A9 was expressed in E coli and purified as described 
previously [41]. Its concentration was determined by using 
ε280 = 0.53 (mg/ml)−1cm−1.
Tissue samples
All experimental procedures with tissue samples were 
approved by the medical ethics committees of the Umeå 
University Hospital, Sweden, and by the Human Brain Tis-
sue repository for Neurobiological Studies, National Insti-
tute of Mental Health and Neurosciences, Bangalore, India. 
Brain tissues from seven AD patients with the Braak and 
Braak [5] stages from III to VI, two severe TBI patients of 
35 and 51 years, deceased within 72 h after an accident, and 
two non-demented control patients—a 75-year-old female, 
deceased from pulmonary embolism, and a 67-year-old 
female, deceased from coronary infarction, were examined. 
All tissues were from the temporal lobe, including the hip-
pocampus, the dentate gyrus, subiculum and also the neo-
cortex. They were paraffin-embedded and microtome-sec-
tioned to 7-μm-thick slices.
Immunohistochemistry
Single and sequential immunohistochemistry on the same 
tissue sections was performed as described previously 
[15] with some modifications [29]. The following antibod-
ies were used: Aβ (rabbit polyclonal, AS08 328, 1 in 200, 
Agrisea), S100A9 (rabbit polyclonal, sc-20173, 1 in 100, 
Santa Cruz Biotechnology), S100B (mouse monoclonal, 
9A11B9, 1 in 100, Santa Cruz Biotechnology), phospho-
rylated-tau (mouse monoclonal, AT8, 1 in 25, Thermo Sci-
entific), fibrillar and A11 (rabbit polyclonal, 1 in 200, gift 
from Kayed [21]), NeuN (mouse monoclonal, MAB377, 
1 in 100, Millipore), gFAP (chicken polyclonal, astrocyte 
marker ab4674, 1 in 500, Abcam), goat anti-chicken IgY 
(ab97135, 1 in 2000, Abcam), anti-mouse (MP-7402) and 
anti-rabbit Igg peroxidase reagent kits (MP-7401), Vector 
laboratories. The tissues were scanned by a Pannoramic 
SCAN slide scanner 250 (3D Histech).
Atomic force microscopy
Atomic force microscopy (AFM) imaging was carried 
out by a BioScope Catalyst AFM (Bruker) in peak force 
mode in air at a resonance frequency of ca. 70 kHz and a 
resolution of 256 × 256 pixels; scan sizes were from 0.5 
to 10 μm. Amyloid samples were deposited on the surface 
of freshly cleaved mica (Ted Pella) for 15 min, washed 3× 
with 100 μl deionized water and dried at room temperature.
Fluorescence assays
Thioflavin T (ThT) and 1-anilinonaphthalene-8-sulfonic 
acid (ANS) assays were carried out as described previously 
[45] by using a FP 6500 spectrofluorometer (Jasco) with 
excitation at 440 and 365 nm and detecting emission at 485 
and 470 nm, respectively; 5 nm excitation and emission 
slits were used in both cases.
Cell culture experiments
SH-SY5Y neuroblastoma cells were cultured with and 
without amyloids as described previously [20]. Cell via-
bility was measured by WST-1 assay (roche) after 24 h 
co-incubation with amyloids. Absorbance at 450 nm was 
measured by a plate reader (Tecan). Cell viability was 
expressed as a percentage of the absorbance in wells con-
taining treated cells compared to those of control untreated 
cells. The amyloid samples prepared for cytotoxicity exper-
iments were lyophilised and reconstituted directly prior to 
adding to the cells in PBS and added to cell culture media 
at the required concentration. The morphology of amyloid 
structures was not affected by lyophilisation as examined 
by AFM imaging.
NMr
NMr measurements were performed on a Bruker Avance 
500 MHz spectrometer equipped with a triple-resonance 
Bruker CryoProbe including a z-axis gradient coil. Dif-
fusion measurements on a 100 μM S100A9 sample in 
10 mM PBS buffer (pH 7.4; 10/90 H2O/D2O) were car-
ried out at 25 °C using a bipolar gradient routine (Bruker 
pulse program ledbpgppr2s, using 32 linearly spaced gradi-
ent strengths from 5 to 95 % of maximum strength, with 
100 ms longitudinal storage time and 2 ms bipolar gradi-
ents). The diffusion data for the methyl peak at 0.91 ppm 
were processed and fitted within the Topspin T1/T2 analy-
sis module. The resulting diffusion coefficient was con-
verted into a corresponding hydrodynamic radius by using 
the Stokes–einstein equation. One-dimensional 1H and 
two-dimensional 1H-15N heteronuclear single quantum 
coherence (HSQC) spectra of 75 μM 15N-labeled Aβ in 
10 mM PBS (pH 7.3; 90/10 H2O/D2O) were recorded at 
25 °C both before and after addition of 75 μM S100A9. 
The assignment of Aβ(1–40) amide peaks was performed 
previously [9]. The weighted average of the 1H and 15N 
chemical shift difference (Δδ = (0.5[Δδ(1H)2 + (0.2Δδ 
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(15N))2])1/2) and the ratio of amide peak intensities meas-
ured before and after addition of S100A9 were calculated.
Dynamic light scattering
Samples were analyzed on a Zetasizer Nano (Malvem) 
DlS instrument by scattered light at 630 nm and under 
173° angle. 50 μM S100A9 in 400 μl PBS was subjected 
to five repetitive measurements. Hydrodynamic diameter 
was evaluated from the autocorrelation curves fitted with 
the manufacturer’s software and molecular weight was cal-
culated by the Protein Utilities program provided by the 
manufacturer.
Molecular docking
The S100A9 dimer [18] and Aβ(1–40) monomer [39] were 
taken as the receptor and ligand, respectively. The Patch-
dock [35] and Firedock [1] docking programs were applied 
to find possible binding modes. 17,316 binary models were 
generated by Patchdock and further optimized by Firedock. 
177 binding modes with a docking score lower than −20 
were shown.
Results
S100A9 in plaques in the hippocampal and neocortical 
areas in AD and TBI
Sections from the AD hippocampi and neocortical areas of 
seven patients with the Braak and Braak stages from III to 
VI were analyzed for the distribution and co-localization of 
pro-inflammatory and amyloid antigens by using sequen-
tial immunohistochemistry as shown in the representa-
tive images with a higher magnification in Figs. 1, 2 and 
in the broader low-magnification views in online supple-
mental files 1 and 2, respectively. We found that S100A9 
is abundantly present throughout the whole hippocampi of 
AD patients, including amyloid plaques, extensive regions 
around them and blood vessels (Fig. 1a and supplemental 
file 1a). By contrast, the staining with Aβ antibodies was 
localized only in the plaques and blood vessels, but not in 
the surrounding tissues (Fig. 1b and supplemental file 1b). 
The immunostaining for glial-specific S100B protein was 
also performed for comparison, as this most studied protein 
from the S100 family is commonly associated with neurode-
generative disorders and TBI. Interestingly, the staining with 
S100B antibodies did not overlap with the S100A9 and Aβ 
patterns: S100B was not detected in plaques and blood ves-
sels, but local staining was observed in tissues surrounding 
the plaques (Fig. 1c), limited staining was detected around 
the blood vessel walls and in the white matter of the alveus 
of hippocampus (supplemental file 1c, low right corner). We 
have examined the same tissues by immunostaining with 
gFAP astrocyte-specific antibodies and detected the pres-
ence of astrocytes around amyloid plaques. The gFAP-pos-
itive pattern showed partial overlap with some local S100B 
immunostaining (Fig. 1c, d) due to the fact that S100B is 
produced primarily by mature astrocytes [43]. Staining with 
anti-amyloid fibrillar antibodies showed a clear correlation 
with Aβ and S100A9 depositions within the plaques and 
blood vessels as shown on the individual and overlapping 
summary images (Fig. 1e, k and supplemental file 1d, i).
Similar to the AD hippocampi, the neocortical areas 
of AD brains have also shown an abundance of Aβ and 
S100A9 amyloid plaques, in which the immunostain-
ing pattern for Aβ, S100A9 and fibrillar antibodies were 
perfectly overlapped (Fig. 2a, b, e and supplemental file 
2). generally, a higher level of S100A9 expression was 
found also in the surrounding plaque regions, which were 
not stained, however, with Aβ antibodies. The S100B and 
gFAP staining was observed in the areas neighboring the 
plaques, but not in the plaques themselves, with partial 
overlapping (Fig. 2c, d) as indicated above for the AD hip-
pocampi (Fig. 1c, d). We did not observe any noticeable 
correlation between the distribution of the Aβ-S100A9 
amyloid plaques in the brain tissues and the Braak and 
Braak stages (III–VI) of AD. The Aβ and/or S100A9 amy-
loid plaques were not found in the hippocampi and cortical 
areas of the two non-demented control patients as shown 
in the representative immunohistochemical staining images 
for S100A9 in supplemental files 3a, b.
It is important to note that we have also examined the 
presence of S100A8 plaques in the AD hippocampi and 
cortical areas, as S100A8 and S100A9 tend to form het-
erocomplexes in many but not all tissues [13, 40]. We have 
not found any S100A8-positive plaques in the CA1, CA3, 
CA4, dental gyrus and neocortical areas (supplemental files 
3c–f), while by contrast we have observed the S100A9-
positive plaques in all these areas, respectively (supplemen-
tal file 3g–j).
As TBI is viewed as a risk factor and a potential pre-
cursor state for AD, the immunohistochemical analysis for 
the same antigens were performed on two TBI patients, 
who deceased within 72 h after the accidents. For both 
individuals the immunohistochemistry revealed the pres-
ence of numerous S100A9 plaques throughout the whole 
hippocampi (Fig. 3a) as well as their relatively random 
presence in the neocortical areas close to the hippocampi. 
By contrast, these plaques were not reactive to antibodies 
against Aβ, amyloid fibrils and S100B (data not shown), 
but were stained with A11 anti-amyloid oligomeric anti-
bodies (Fig. 3b). This indicates that S100A9 is not only 
secreted, but also very rapidly aggregates into amyloid-like 
plaques in TBI.
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S100A9 in neurons in the hippocampal and neocortical 
areas in AD and TBI
Apart from the plaques and their surrounding areas, we 
observed also distinct positive staining with S100A9 anti-
bodies of neuronal cells in the AD, TBI and control aged 
brain tissues; all S100A9-positive cells displayed specific 
neuronal morphology. Figure 3c, e demonstrates a repre-
sentative immunostaining of pyramidal neurons in the CA3 
and neurons in the dentate gyrus regions of one TBI patient 
and similarly the S100A9-positive neurons were observed 
throughout the whole TBI hippocampus including also the 
CA1, CA2 and CA4 areas as well as the neocortex. The 
neurons in the following tissue slice from the same region 
were also intensively stained with the NeuN neuron-spe-
cific antibodies, verifying that these are indeed neuronal 
cells (Fig. 3d). The S100A9-positive neurons were also 
observed in the non-demented control patients; the repre-
sentative staining of granular neurons in the dentate gyrus 
is shown in Fig. 3f, though the S100A9-positive neurons 
were observed also in other areas of the hippocampus and 
neocortex. In the AD patients the S100A9-positive neu-
rons were abundant in all regions of the hippocampus and 
neocortex as shown in Fig. 3g for the CA4 region and in 
supplemental file 3g–j for other areas of the hippocampus 
and neocortex. It is important to note, that some neuronal 
cells stained with S100A9 antibodies showed also staining 
with Aβ antibodies, as demonstrated in the representative 
images in Fig. 3g, h, signifying that S100A9 and Aβ can 
co-aggregate also within the neuronal cells. By contrast, we 
have observed an inverse correlation between S100A9 and 
phosphorylated-tau immunostaining, i.e., neurons inten-
sively stained for S100A9 showed no staining with phos-
phorylated-tau antibodies (supplemental file 4), indicating 
that S100A9 is not linked to AD tau-pathology.
Co-aggregation of S100A9 and Aβ(1–40)
The amyloid formation of individual Aβ(1–40) and S100A9 
as well as their mutual effects on each other were examined 
in vitro in 10 mM PBS, pH 7.4, 37 °C under 100 rpm shak-
ing (Fig. 4). It has been reported previously that the theo-
retical amyloid propensity score of S100A9 is close to the 
propensity of Aβ(1–40) [45]. Indeed, as assessed by AFM 
imaging, after 24 h incubation S100A9 (50 μM) aggregated 
into thin protofilaments, which displayed bead-on-string 
morphology (Fig. 4a); they were less than 1 nm in height 
as measured by AFM cross-section analysis (Fig. 4i). After 
3 days incubation these protofilaments developed into very 
Fig. 1  S100A9 and Aβ plaques in the AD hippocampus. repre-
sentative sequential immunohistochemistry of the AD hippocampus 
tissue with a S100A9, b Aβ, c S100B, d gFAP and e fibril-specific 
antibodies. The corresponding images are shown in pseudo-color: f 
S100A9 staining in green; g Aβ in yellow; h S100B in blue; i gFAP 
in magenta and j fibrillar in red. k Superposition of pseudo-color lay-
ers. Scale bars are 50 μm in all images
◂
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coily, smooth fibrils (Fig. 4b) of ca. 3 nm height in AFM 
cross-section and up to a micron length (Fig. 4j). Aβ(1–40) 
(20 μM) also formed thin protofilaments of ca. 1 nm height 
with beaded morphology after 24 h incubation (Fig. 4c 
and supplemental file 5a). By contrast, in the mixture of 
S100A9 and Aβ(1–40) (50 and 20 μM, respectively), the 
mature amyloid fibrils were fully developed during the 
same time period with a thickness of 10 nm and larger and 
of micron length and longer (Fig. 4d and supplemental file 
5b). This clearly demonstrates that S100A9 and Aβ(1–40) 
drastically enhance each other’s amyloidogenicity.
It is important to note that similar fibrils were devel-
oped when Aβ(1–40) (20 μM) was added to pre-incubated 
S100A9 (50 μM) protofilaments (Fig. 4a) and subjected to 
further incubation for 24 h (supplemental files 5c, d). This 
indicates that preformed amyloid aggregates of S100A9 
can serve as templating surfaces for Aβ(1–40) amyloid 
assembly.
When S100A9-Aβ(1–40) co-aggregation (20 μM each) 
was monitored on a longer time scale, the mature fibrils 
with ca. 10 nm height were assembled after 24 h (supple-
mental files 5e, h), then they developed further into mas-
sive fibrillar bundles decorated by globular species after 
48 h (Fig. 4e and supplemental file 5 g) and subsequently 
into super-bundles with ca. 80 nm height, as measured by 
AFM cross-section, after 72 h (Fig. 4f and supplemental 
file 5 h). With a higher content of S100A9 (100 μM) in the 
S100A9-Aβ(1–40) solution, even larger aggregated clumps 
were formed on the amyloid scaffolding (supplemen-
tal file 5i). We have reported previously that the S100A8/
A9 complexes form super-fibrillar calcified bundles in the 
aging prostate able to withstand its protease-rich environ-
ment [45]. Similarly, S100A9 and Aβ(1–40) can also pro-
mote each other’s amyloid assembly into joint large super-
complexes. It is important to note, that Aβ(1–40) alone, 
incubated even at 100 μM concentration for 24 h and up to 
7 days, formed mature fibrils but they were still less thick, 
with ca. 6 nm height in AFM cross-sections (supplemental 
files 5j, k), and remained smooth compared to the coated 
fibrillar bundles of S100A9-Aβ(1–40) discussed above.
A drastically different morphology of S100A9-Aβ(1–40) 
complexes was observed when their concentration was 
increased to 100 μM each and the shaking rate was raised 
to 500 rpm. Then S100A9-Aβ(1–40) formed highly popu-
lated, very regular, rosette-like structures of up to 2 μm in 
Fig. 2  S100A9 and Aβ plaques in the AD neocortex. representative 
sequential immunohistochemistry of the AD neocortical tissue with a 
S100A9, b Aβ, c S100B, d gFAP and e fibril-specific antibodies. The 
corresponding images are shown in pseudo-color: f S100A9 staining 
in green; g Aβ in yellow; h S100B in blue; i gFAP in magenta and j 
fibrillar in red. k Superposition of pseudo-color layers. Scale bars are 
50 μm in all images
▸
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diameter and with 10 nm height in the center (Fig. 4g, h 
and supplemental file 5l). This demonstrates that if protein–
protein interactions become more favorable due to higher 
concentration and higher rate of diffusion, the radial nucle-
ation and growth can kinetically out-compete the linear 
fibrillar assembly.
The ThT fluorescence assay, reflecting specific binding 
of ThT dye to cross-β-sheet containing amyloids, showed a 
pronounced increase of ThT fluorescence in all 24-h incu-
bated amyloid samples of S100A9, Aβ(1–40) and S100A9-
Aβ(1–40), compared to freshly dissolved polypeptides. 
The highest ThT fluorescence signal was observed in the 
Fig. 3  S100A9 in the TBI hippocampal plaques and in TBI, con-
trol and AD neurons. a Immunohistochemistry of amyloid plaques 
with S100A9 antibodies and b with A11 oligomer-specific antibod-
ies in the TBI hippocampus. c Staining of hippocampal neurons with 
S100A9 and d with NeuN neuron-specific antibodies in TBI. e rep-
resentative staining of neurons in the TBI and f the non-demented 
dentate gyrus with S100A9 antibodies. g representative sequential 
staining of pyramidal neurons in the CA4 region in AD with S100A9 
antibodies and h the same neurons were stained with Aβ antibod-
ies. The same plaques and neurons in sequential tissue sections are 
indicated by black (a, c, g) and red (b, d, h) arrows. Scale bars are 
100 μm in all images
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S100A9-Aβ(1–40) solution reflecting the development of 
large quantities of mature fibrils (Fig. 4k).
Protein surface hydrophobicity was examined by ANS 
binding assay monitoring the increase of dye fluorescence 
upon binding to hydrophobic surfaces (Fig. 4l). Both 
freshly dissolved and amyloid species of S100A9 were 
characterized by significantly larger hydrophobic surfaces 
than the respective Aβ(1–40) samples, indicating that in 
the S100A9-Aβ(1–40) mixture S100A9 may be a major 
hydrophobic contributor. This suggests that S100A9 amy-
loids may provide very effective hydrophobic interfaces 
significantly promoting the fibrillation of Aβ(1–40).
Cytotoxicity of S100A9 and Aβ(1–40) amyloids
Since S100A9 is abundant within plaques and hip-
pocampal tissues, we have assessed the cytotoxic dam-
age which S100A9 amyloids can inflict on SH-SY5Y 
Fig. 4  Co-aggregation of S100A9 and Aβ(1–40). a AFM height 
images of S100A9 (50 μM) protofilaments after 24 h incubation in 
10 mM PBS, pH 7.4, 37 °C and with 100 rpm shaking; the same con-
ditions were used in all samples, unless specified. b AFM image of 
S100A9 fibrils after 5 days incubation; c Aβ(1–40) (20 μM) proto-
filaments after 24 h; d fibrils of co-incubated S100A9-Aβ(1–40) (50 
and 20 μM, respectively) after 24 h; e coated fibrils of co-incubated 
S100A9-Aβ(1–40) (both at 20 μM) after 48 h and f after 72 h; g, h 
the rosettes of co-incubated S100A9-Aβ(1–40) (both at 100 μM) 
formed after 24 h upon 500 rpm shaking and shown with different 
magnification; i AFM cross-section of representative amyloid fila-
ment indicated by red arrows in a; f AFM fibrillar cross-section cor-
responding to b; k ThT binding assay; l ANS binding assay. In k, l 
50 μM S100A9 and 20 μM Aβ(1–40) were used; white bars corre-
spond to freshly dissolved polypeptides and black bars to the samples 
incubated for 24 h. All measurements were referenced to the fluores-
cence of correspondent free dyes in solution and were taken as an 
average of five repeats. x, y scale bars are 100 nm (a), 500 nm (b–f) 
and 1 μm (g, h)
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neuroblastoma cells (Fig. 5). The incubation of SH-
SY5Y cells with preformed S100A9 linear and annular 
protofilaments led to a concentration-dependant decrease 
in cell viability to the level of ca. 35 and 29 %, respec-
tively, at final added polypeptide concentration (Fig. 5a). 
By contrast, pre-aggregated Aβ(1–40) caused a less pro-
nounced cell viability decline, i.e., to ca. 67 % level at 
the highest added concentration (Fig. 5b). Moreover, the 
addition of S100A9 (20 μM) co-incubated with increas-
ing concentration of Aβ(1–40) (from 1 to 20 μM), led 
to an Aβ(1–40) concentration-dependent increase of cell 
viability from the level of 35 % (S100A9 alone) to ca. 
72 % [S100A9 co-incubated with 20 μM Aβ(1–40)]. It is 
important to note, that freshly dissolved S100A9 was not 
toxic at 1–2.5 μM, but displayed ca. 18 % toxicity after 
24 h co-incubation with SH-SY5Y cells at 5–20 μM con-
centrations, possibly due to the on-going protein aggrega-
tion under the conditions of the experiments. Specifically, 
examined here linear (ca. 1 nm and less in height) and 
annular protofilaments of S100A9 were produced upon 
24 h incubation in 10 mM PBS, pH 7.4, 37 °C without 
shaking (Fig. 5c, d, f). The rings were highly populated 
upon incubation in less hydrophobic polyacrylic tubes, 
although they were also present in smaller quantities 
together with linear protofilaments in four repetitive 
preparations. They were characterized by ca. 1–1.2 nm 
height and ca. 20 nm diameter measured between high-
est points on their circumferences in AFM cross-sections 
(Fig. 5e) and closely resembled amyloid pores of Aβ 
and α-synuclein reported previously [24]. The Aβ(1–40) 
amyloid protofilaments (ca. 2 nm height) and thicker 
S100A9-Aβ(1–40) fibrils (ca. 4–5 nm height) were pro-
duced under the same conditions and are presented in 
Fig. 5g, h, respectively. As the co-incubation of S100A9 
and Aβ(1–40) leads to formation of thicker mature fibrils 
and potentially even larger aggregates, as we discussed 
above (Fig. 4), these effectively mitigate the higher cyto-
toxicity of S100A9 protofilaments (Fig. 5b).
Fig. 5  Cytotoxicity of S100A9-Aβ(1–40) amyloids. a Viability of 
SH-SY5Y neuroblastoma cells measured by WST-1 assay after 24 h 
co-incubation with S100A9 amyloids. The viability of untreated 
cells is taken as 100 %. White bars correspond to cells treated with 
S100A9 linear protofilaments, black bars—with S100A9 annular 
protofilaments. Bulk S100A9 concentration in μM is shown along 
x-axis. b Viability of SH-SY5Y cells measured by WST-1 assay 
after 24 h co-incubation with Aβ(1–40) and S100A9-Aβ(1–40) amy-
loids. Dashed bars correspond to cells treated with Aβ(1–40) amy-
loids and grey bars—with co-aggregated S100A9-Aβ(1–40). Grey 
bar at zero concentration corresponds to the viability in the presence 
of 20 μM S100A9 amyloids as in a. Bulk Aβ(1–40) concentration 
in μM is shown along x-axis. S100A9 was present at 20 μM in all 
co-incubated S100A9-Aβ(1–40) samples. *p = 0.04, **p = 0.0016, 
***p = 0.0003. c AFM height image of S100A9 (20 μM) proto-
filaments assembled in polypropylene tubes and subjected to cyto-
toxicity assay after 24 h incubation in 10 mM PBS, pH 7.4, 37 °C 
without shaking; the same incubation conditions were used in other 
samples. d AFM cross-section of amyloid protofilament indicated by 
red arrows in c and e AFM cross-section corresponding to f image. f 
AFM height image of S100A9 (20 μM) rings formed in more hydro-
philic polyacrylic tubes; insertion of 80 × 80 nm shows an individual 
S100A9 ring. g AFM height image of Aβ(1–40) (20 μM) protofila-
ments and h S100A9-Aβ(1–40) (both at 20 μM) amyloid aggregates. 
x, y scale bars are 100 nm in all images
516 Acta Neuropathol (2014) 127:507–522
1 3
Co-aggregation and cytotoxicity of S100A9 and Aβ(1–42) 
amyloids
We have examined also the co-aggregation and gained 
cytotoxicity of S100A9 and Aβ(1–42) amyloids, since 
this peptide together with Aβ(1–40) plays a central role 
in AD pathogenesis [19]. S100A9 was co-incubated with 
a range of concentrations of Aβ(1–42) from 1 to 20 μM 
prior subjecting these species to the cytotoxicity experi-
ments. The cytotoxic samples of Aβ(1–42) developed 
upon 7 h incubation in 10 mM PBS, pH 7.4 and 37 °C 
were characterized by the presence of oligomers and thin 
protofilaments with <1 nm height as shown in Fig. 6a. 
Upon longer incubation Aβ(1–42) has developed mature 
fibrils; a representative image is shown in Fig. 6b with a 
height in the AFM cross-section of ca. 3 nm. By contrast, 
co-incubation of even 2.5 μM Aβ(1–42) with 20 μM 
S100A9 led to the formation of much thicker coated 
fibrils with the variable height in the AFM cross-section 
from 4–5 to 10–13 nm (Fig. 6c). The same type of coated 
fibrillar aggregates was observed upon co-incubation 
of higher concentrations of Aβ(1–42) with S100A9 and 
persisted on a longer time scale as shown in the repre-
sentative image of co-aggregation of 10 μM Aβ(1–42) 
with 20 μM S100A9 after 48 h (Fig. 6d). Similar to the 
co-aggregation of S100A9 with Aβ(1–40), the complexes 
of Aβ(1–42) and S100A9 produced at 1:4 and 1:2 molar 
ratios showed significantly higher ThT signal compared 
to the individual components incubated during the same 
period of 24 h (Fig. 6e).
Fig. 6  Co-aggregation and cytotoxicity of S100A9 and Aβ(1–42) 
amyloids. a AFM height images of Aβ(1–42) (10 μM) oligomers and 
protofilaments formed after 7 h incubation in 10 mM PBS, pH 7.4, 
37 °C without shaking. The same conditions were used in all sam-
ples, unless specified. b AFM height image of Aβ(1–42) (20 μM) 
fibril after 24 h incubation; insertion shows the fibrillar height in the 
AFM cross-section indicated by red arrow. c AFM 3D image of co-
aggregated “coated” fibrils of Aβ(1–42)-S100A9 (2.5 and 20 μM, 
respectively) produced after 24 h. d AFM height images of co-aggre-
gates of Aβ(1–42)-S100A9 (10 and 20 μM, respectively) persisted 
after 48 h co-incubation. e ThT binding assay for 5 and 10 μM Aβ(1–
42) and 20 μM S100A9, respectively, incubated for 24 h. All meas-
urements were referenced to the fluorescence of correspondent free 
dyes in solution and were taken as an average of three repeats. Spe-
cific samples are indicated along x-axis. x, y scale bars are 1 μm (a), 
500 nm (b, d) and 200 nm (c). f Viability of SH-SY5Y neuroblastoma 
cells measured by WST-1 assay after 24 h co-incubation with Aβ(1–
42) and S100A9 amyloids. The viability of untreated cells is taken as 
100 %. Bulk Aβ(1–42) concentration in μM is shown along x-axis. 
S100A9 was at 20 μM in all experiments. Olive bars correspond to 
cells treated with co-aggregated Aβ(1–42)-S100A9; bars with hori-
zontal stripe pattern—to cells treated with Aβ(1–42) oligomers and 
protofilaments formed after 7 h (Fig. 6a); bars with diagonal stripe 
pattern—to cells treated with Aβ(1–42) mature fibrils formed after 
24 h (b). *p = 0.026, ***p = 0.0003
517Acta Neuropathol (2014) 127:507–522 
1 3
The measurements of the SH-SY5Y cell line viability in 
the presence of oligomers and protofilaments of Aβ(1–42) 
showed decrease by up to ca. 40 % upon increasing amy-
loid concentrations (Fig. 6a, f), while the fibrils of Aβ(1–
42) were not toxic (Fig. 6b, f). This is consistent with the 
previously published results [19]. It is interesting to note, 
that co-aggregation of S100A9 with Aβ(1–42) leading to 
the formation of thick coated aggregates resulted in the 
complete elimination of the Aβ(1–42) and S100A9 amy-
loid cytotoxicity already at 1:8 molar ratio of Aβ(1–42) and 
S100A9 (Fig. 6f). This is a significantly more pronounced 
mitigating effect on S100A9 amyloid cytotoxicity than 
in the case of co-aggregation of Aβ(1–40) and S100A9, 
as then even at 1:1 molar ratio the cell viability remained 
30 % lower compared to controls (Fig. 5b).
Interactions of native S100A9 and Aβ
The interactions of native S100A9 and Aβ(1–40) (selected 
as a representative Aβ peptide) were analyzed by using 
solution NMr and molecular docking. The initial state of 
S100A9 was evaluated by using NMr diffusion (Fig. 7a) 
and dynamic light scattering (not shown), which both con-
sistently demonstrated that this is a dimer with a molecu-
lar weight of ca. 27 kDa and hydrodynamic radius of ca. 
3 nm, respectively. The latter indicated also that ca. 1 % 
of protein is present in aggregated state. The broad NMr 
signals in 1D 1H NMr spectrum of native S100A9 suggest 
that there is a chemical exchange and dynamic equilibrium 
between the monomeric and dimeric forms (Fig. 7b).
2D 1H-15N HSQC spectra of 75 μM Aβ(1–40) were 
recorded before and after addition of S100A9. The spectra 
reflect an essentially monomeric and unstructured form of 
Aβ(1–40) [42]. Small chemical shifts (ca. 0.015 ppm) for 
residues K16, e22, S26, K28, g29, together with a 20–
30 % decrease in peak intensity for some central Aβ(1–40) 
residues (e.g., K28), indicate a possible transient binding 
site in this central region (Fig. 7c–e).
The analysis of interactions between S100A9 dimer 
and Aβ(1–40) monomer by molecular docking is shown 
in Fig. 8a. A total of 177 binding modes of Aβ(1–40) were 
superimposed on the S100A9 dimer, which were selected 
based on their docking scores lower than −20. The cor-
responding binding interfaces involve the two faces of 
S100A9 dimer, each composed of helix I and helix III′ 
(helix III′ from the other protomer). Structural cluster-
ing analysis for these 177 binding modes with a cutoff of 
0.2 nm showed that there are 118 clusters with the largest 
cluster consisting of 12 members. The multiple cluster-
ing without dominant clusters indicates that the binding 
between S100A9 dimer and Aβ(1–40) has a diffusive char-
acter as opposed to specific docking. The S100A9 residues, 
Fig. 7  Interaction of native 
S100A9 and Aβ(1–40) exam-
ined by NMr. a NMr diffusion 
of S100A9 measured at 25 °C. 
Methyl peak intensities at 
0.91 ppm in a.u. are shown 
as a function of gradient field 
strength G, cm−1. b 1D 1H 
NMr spectrum of S100A9. c 
2D 1H-15N HSQC spectra of 
Aβ(1–40) prior (blue) and after 
(red) addition of S100A9. d 
Differences in Aβ(1–40) chemi-
cal shifts induced by S100A9 
binding versus Aβ(1–40) amino 
acid residue numbers. e ratios 
of Aβ(1–40) amide peak intensi-
ties measured in the presence 
(I) and in the absence (Io) of 
S100A9 versus Aβ(1–40) amino 
acid residue numbers
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such as H2O from helix I, D30 from the linker between 
helices I and II and r85 and l86 from helix III, were found 
to make particularly close contacts with Aβ(1–40). On the 
Aβ(1–40), residues H14, F20 and K28 from the middle 
and V39 and V40 from the C-terminus are primary candi-
dates for the interaction with S100A9. This is consistent 
with NMr results, where 2D 1H-15N-HSQC measurements 
showed that S100A9 interactions induce chemical shift 
changes and reduced signal intensities in central Aβ(1–40) 
residues, particularly K28 (Fig. 7c–e). Both S100A9 and 
Aβ(1–40) interfaces and in particular S100A9 helices I and 
III include significant clustering of positive and negative 
charges as well as aromatic amino acid residues. There-
fore, transient interactions between S100A9 and Aβ(1–40) 
may include electrostatic component, guiding them towards 
each other, and hydrophobic binding, providing the inter-
face for Aβ(1–40) molecules diffusion and self-assembly 
into amyloid structures.
Discussion
Pro-inflammatory mediator S100A9 was identified as 
potential contributor to AD development in patients [23, 
37] and mice models [16] and to inflammation-depend-
ent aging in the human body [38]. The understanding of 
S100A9 mechanisms of action is still at a very early stage 
and this knowledge is critical as S100A9 can serve both as 
a risk factor and therapeutic target in AD diagnostics and 
treatment. Indeed, regularly administered general anti-
inflammatory drugs, used to treat concomitant diseases, 
produce also a positive effect on AD, slowing down its 
progression [7, 26]. Here, we have shown that S100A9 is 
highly abundant in AD brain (Figs. 1, 2 and supplemental 
files 1–3), and due to its inherent amyloidogenicity it can 
play a key role in AD development. Specifically, S100A9 
can be a trigger and an important contributor to plaque for-
mation and neurotoxicity. Immunohistochemical analysis 
demonstrated that together with Aβ peptide S100A9, but 
not another well-known brain inflammatory protein S100B, 
is consistently present in the AD plaques and amyloid 
deposits in the blood vessel walls, forming co-aggregates 
reactive with anti-fibrillar antibodies. S100A9 is also abun-
dant in tissues surrounding amyloid deposits (Figs. 1, 2 and 
Fig. 8  Molecular interactions of S100A9 and Aβ peptides and their 
role in AD. a Molecular docking of S100A9 dimer and Aβ(1–40) 
monomer. Backbones of S100A9 dimer and Aβ(1–40) are shown 
in red ribbons and green beads, respectively. 177 best ranked bind-
ing modes of Aβ(1–40) are superimposed. Upper and lower panels 
show the side and top views, respectively. Helices I and III as binding 
candidates are indicated. b Schematic summary of multiple amyloid 
pathways of S100A9, Aβ peptides and co-aggregated S100A9-Aβ. 
The aggregated structures of individual polypeptides are outlined in 
red; in co-aggregated complexes S100A9 is schematically denoted in 
yellow and Aβ—in blue. c Schematic outline of the role of S100A9 
in AD amyloid-neuroinflammatory cascade. Soluble Aβ peptides 
(shown in blue) and S100A9 (in yellow) secreted by neurons and 
activated microglia (A-Mi) are toxic to neurites and synapses. They 
accumulate into senile amyloid plaques, which recruit microglial 
cells. Microglia is further activated by S100A9 via the Tlr 4 and 
rAge signaling pathways. level of S100A9 rises, leading to its fur-
ther amyloid deposition. The cycle is completed as shown by green 
arrows
▸
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supplemental files 1–2), indicating that an elevated level of 
S100A9 can favor its aggregation and deposition.
remarkably, in TBI hippocampi the numerous plaques 
that rapidly developed within less than 72 h post-accident 
were composed of S100A9 on its own, but not with Aβ. 
These plaques were reactive with A11 amyloid oligomer 
antibodies, indicating that already within this short time 
period S100A9 has undergone amyloid-type conforma-
tional changes (Fig. 3a, b). It is important to note that apart 
from catastrophic brain injuries, head traumas are common 
in various sports and have received increasing attention 
due to their neuropathological consequences and similari-
ties with AD [3]. TBI is considered also as a potential risk 
condition for AD development. In AD pathology the amy-
loid cascade is a central hypothesis and amyloid plaques 
are a major pathological hallmark of disease, respectively, 
with the chief role in these phenomena designated to Aβ. 
We have demonstrated here that highly amyloidogenic 
S100A9 is able to form amyloid structures in vitro just as 
rapidly as Aβ (Figs. 4, 5). S100A9 and its amyloids are 
also more hydrophobic than Aβ (Fig. 4l) and if the plaques 
fulfill the function of a sink for various toxic species and 
cell debris not cleared by cellular machineries, S100A9 is 
a perfect candidate for the role of plaque-forming protein, 
able to sequestrate all these materials on its sticky hydro-
phobic surfaces. S100A9 also readily co-aggregates with 
both Aβ(1–40) and Aβ(1–42) and promotes their amyloid 
deposition (Figs. 4, 5, 6). Therefore, the amyloid plaques of 
S100A9 rapidly developed in TBI brain, in fact, can serve 
as the precursors of AD amyloid plaques, linking TBI and 
AD via the amyloid cascade mechanism.
S100A9 is secreted by macrophages and the activated 
microglia in inflammation-associated AD can produce a 
significantly elevated level of S100A9, which can locally 
exceed the Aβ level. The initial form of S100A9 is pri-
marily homodimers as we have shown by NMr diffusion 
experiments and dynamic light scattering, though the broad 
lines in 1D NMr spectrum indicate that there is an equilib-
rium exchange between monomers and dimers. However, 
S100A9 does not stay in its native state for long and within 
hours or days under close to physiological conditions in 
vitro (pH 7.4 and 37 °C) it forms a plethora of amyloid 
complexes, including linear and annular amyloid protofila-
ments and flexible fibrils (Figs. 4, 5). remarkably, S100A9 
protofilaments and especially its annular species closely 
resemble similar amyloid structures of leading amyloid 
polypeptides such as Aβ and α-synuclein in AD and Parkin-
son’s disease, respectively (Fig. 5, [24]) and they are also 
cytotoxic towards SH-SY5Y neuroblastoma cells (Fig. 5). 
However, the toxicity of S100A9 amyloids subsides if 
S100A9 is pre-incubated with an increasing concentra-
tion of Aβ(1–40) and is completely eliminated during co-
incubation with Aβ(1–42), starting from their molar ration 
of 1:8 for Aβ(1–42) and S100A9, respectively. This occurs 
due to their co-aggregation into larger aggregated species 
and Aβ(1–42) apparently is more potent in this regard than 
Aβ(1–40) (Figs. 5, 6). Native freshly dissolved S100A9 by 
itself also showed some cellular toxicity (ca. 18 %), but 
due to its progressing aggregation under the conditions of 
experiment, this toxicity may be related to its aggregates.
even larger plethora of amyloid species were formed 
when S100A9 and Aβ(1–40) or Aβ(1–42) were co-aggre-
gated together as shown in Figs. 4, 5, 6 and schemati-
cally summarized in Fig. 8b. Since amyloid formation is a 
concentration-dependent as well as a thermodynamically 
and kinetically controlled process [28], depending on the 
concentration ratio of S100A9 and Aβ, one of them can 
be prompted to aggregate into thermodynamically stable 
aggregates faster than the other. Here, we consider a few 
possible scenarios depending on the concentrations of both 
counterparts and conditions of amyloid formation, such as 
shaking, which may facilitate protein–protein interactions. 
As we have shown above, the amyloid fibrils of S100A9-
Aβ(1–40) (taken at 50 and 20 μM, respectively) displayed 
smooth surfaces and were significantly thicker and longer 
than the fibrils of individual counterparts formed even on a 
longer time scale and also at higher respective polypeptide 
concentration (Fig. 4d and supplemental file 5b). Impor-
tantly, similar smooth and thick fibrils were produced when 
preformed S100A9 amyloid protofilaments (Fig. 4a) were 
added in solution as templates for the Aβ fibrillation (sup-
plemental files 5c, d). Thus, if one of the counterparts is 
prompted to aggregate faster, for example the more hydro-
phobic S100A9, it can provide a hydrophobic templating 
surface for Aβ assembly.
When we mixed S100A9 and Aβ(1–40) at 1:1 ratio and 
20 μM each, instead of smooth fibrils, we have observed 
polymers coated with round-shaped aggregates and the 
thickness of the coat drastically increased upon 72 h incu-
bation, reaching 80 nm (Fig. 4f and supplemental file 5 h). 
It is most likely that an Aβ(1–40) fibrillar surface may 
attract S100A9 coatings, if the former aggregates faster at 
these concentrations of both counterparts. Similar coating 
interactions were observed also when S100A9 was co-incu-
bated with Aβ(1–42) (Fig. 6c, d).
remarkably, when we increased the concentration of 
both S100A9 and Aβ(1–40) to 100 μM and also introduced 
vigorous shaking, new rosette-type regular co-aggregates 
were produced (Fig. 5g). The rosettes were highly populated 
and constituted the dominant amyloid species in the sample; 
they reached up to 2 μm in diameter and displayed a regu-
lar radial pattern of co-aggregation. This may reflect the fact 
that the protein binding process is too rapid to be kinetically 
controlled at more aggregation-prone conditions, thus the 
radial growth will out-compete the more slow linear assem-
bly. Undoubtedly, all these new types of co-aggregated 
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structures require further structural investigation. Here, our 
task was to demonstrate their heterogeneity and the possibil-
ity of refining their properties by varying incubation condi-
tions. It should be also considered that in the affected tissues 
the massive and rapid co-aggregation can be a lesser evil 
as this can effectively remove from circulations more toxic 
and damaging species. We have shown this above by reduc-
ing and eliminating S100A9 amyloid toxicity during its co-
aggregation with increasing concentrations of Aβ(1–40) and 
Aβ(1–42), respectively (Figs. 5b, 6f).
Interestingly, by NMr and molecular docking we 
observed transient or diffusive interactions between 
S100A9 dimer and Aβ monomer, but not their specific 
docking into each other’s surface (Fig. 6a), which would 
also cause a significant perturbation in the 1H-15N HSQC 
spectrum of Aβ (Fig. 5). S100A9 surface hydrophobicity 
and clustering of charged residues, particularly in helices I 
and III, provide, most likely, the interface for Aβ own self-
assembly, rather than promoting strong binding between 
Aβ and S100A9. The opposite, e.g., S100A9 self-assem-
bly on Aβ interface, may also take place as we discussed 
above, depending on the initial conditions and concentra-
tions of both counterparts. Diffusive motility of microtu-
bule and DNA binding proteins may provide an insightful 
analogue for the nature of the diffusive interactions [8]. The 
strong specific binding may ultimately lead to inhibition of 
amyloid formation rather than its promotion as these poly-
peptides have very different non-complementary amino 
acid sequences to be integrated within the same cross-β-
sheet [22].
Importantly, we have observed also consistent immu-
nostaining of hippocampal neurons with S100A9 antibod-
ies in AD, TBI and non-demented aging, indicating that 
S100A9 can be also produced by neuronal cells. In some 
neuronal cells S100A9 was co-localized with Aβ, indi-
cating that their co-aggregation can occur intracellularly 
(Fig. 3g, h). By contrast, intracellular S100A9 is not co-
localized with hypo-phosphorylated tau as it was examined 
by sequential immunostaining of the same tissues (supple-
mental file 4), indicating that S100A9 may not be associ-
ated with tau-pathology, which is another key feature of 
AD. It is interesting to note, that overexpression of S100A8 
and S100A9 was observed in neurons of Kras mutant mice 
model acting as an early trigger of gliosis. In the mutant 
mice cortex the neuronal S100A8/A9 expression pattern 
was clearly associated with increased infiltration by micro-
glia [32]. It is not excluded that similar events can be also 
implicated in the inflammatory cascades in AD and TBI. 
Inflammation clearly occurs in pathologically vulnerable 
regions of AD brain, but the mediators and mechanisms 
playing a key role in this process remained as yet obscure. 
Here, we have demonstrated that S100A9 can act as a link 
between the amyloid and inflammatory cascades (Fig. 8c).
Indeed, during AD plaque formation microglia become 
activated and recruited to the plaque deposition sites [31], 
causing microgliosis. The activated microglia secretes 
S100A9 as well as an array of other pro- and anti-inflam-
matory mediators. This can contribute to changes in neu-
ronal calcium homeostasis [27] and accelerate neuritic and 
synaptic dysfunction [46]. As a result, S100A9 expression 
in neuronal cells can be also turned on, which further acti-
vates microglia via the toll-like receptor 4 (Tlr 4) and 
receptor for advanced glycation end products (rAge) 
signaling pathways [32, 33]. A significantly raised level of 
extracellular S100A9 promotes its amyloid aggregations 
and also co-aggregation with Aβ. Protofilaments of S100A9 
itself are highly neurotoxic (Fig. 5a) and are able to inflict 
rapid damage and death to neurons. As the co-aggregation 
of S100A9 with Aβ(1–40) or Aβ(1–42) proceeds more effi-
ciently than for individual counterparts, the co-aggregation 
process may act as an emergency sink, rapidly removing 
from circulation the neurotoxic amyloid species of both 
polypeptides as well as native S100A9 able to act as Tlr 
4 and rAge activator. The ultimate price for this “rescue” 
clearance process, however, can be the exacerbated growth 
of the amyloid plaques in AD brain. It is known from our 
previous studies that the amyloid complexes of S100A9 are 
much more stable and protease resistant compared to amy-
loids of other proteins [45] and their clearance and removal 
may be therapeutically unachievable. Furthermore, the 
plaques themselves may exacerbate microglia activation, 
thus completing the vicious circle of amyloid-neuroinflam-
matory cascade (Fig. 8c).
Due to its amyloidogenicity, neurotoxicity and signaling 
functions, S100A9 may be a promising therapeutic target. 
Bearing in mind its multifaceted nature, the most effective 
way would be to target in the first instance its overexpres-
sion and secretion rather than deal with subsequent clear-
ance of its multiple native and amyloid species, especially 
as the latter can be extremely stable and resistant to any 
interventions. Detailed studies of the effect of non-steroidal 
anti-inflammatory drugs on S100A9 system, which have 
already proved to be useful in slowing AD, may hold the 
key to effective AD treatment.
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